EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

Marjorie G. Zauderer, Peter W. Szlosarek, Sylvestre Le Moulec, Sanjay Popat, Paul Taylor, David Planchard, Arnaud Scherpereel, Marianna Koczywas, Martin Forster, Robert B. Cameron, Tobias Peikert, Evren Kocabaş Argon, Neil R. Michaud, Attila Szanto, Jay Yang, Yingxue Chen, Vikram Kansra, Shefali Agarwal, Dean A. Fennell

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences